|
Autolus Therapeutics Plc (Autl) Valation DCF
GB | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Autolus Therapeutics plc (AUTL) Bundle
Conçu pour la précision, notre calculatrice DCF (AUTL) vous permet d'évaluer la valorisation d'Autolus Therapeutics plc à l'aide de données financières réelles, offrant une flexibilité complète pour modifier tous les paramètres clés pour des prédictions améliorées.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9 | .2 | 2.3 | 6.2 | 1.7 | 1.8 | 2.0 | 2.2 | 2.4 | 2.6 |
| Revenue Growth, % | 0 | -91.68 | 862.81 | 165.84 | -72.59 | 8.93 | 8.93 | 8.93 | 8.93 | 8.93 |
| EBITDA | -134.4 | -160.5 | -132.0 | -135.5 | -156.8 | -1.8 | -2.0 | -2.2 | -2.4 | -2.6 |
| EBITDA, % | -4621.63 | -66325.62 | -5665.49 | -2188.18 | -9232.63 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 4.6 | 5.7 | 8.5 | 7.4 | 6.6 | 1.8 | 2.0 | 2.2 | 2.4 | 2.6 |
| Depreciation, % | 158.56 | 2375.62 | 366.87 | 119.83 | 386.63 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -139.0 | -166.3 | -140.6 | -143.0 | -163.3 | -1.8 | -2.0 | -2.2 | -2.4 | -2.6 |
| EBIT, % | -4780.19 | -68701.24 | -6032.36 | -2308.01 | -9619.26 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 210.6 | 153.3 | 310.3 | 382.4 | 239.6 | 1.8 | 2.0 | 2.2 | 2.4 | 2.6 |
| Total Cash, percent | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 30.5 | 29.7 | .1 | .2 | 1.0 | 1.0 | 1.1 | 1.2 | 1.3 | 1.4 |
| Account Receivables, % | 1049.66 | 12266.53 | 2.92 | 2.47 | 61.66 | 53.41 | 53.41 | 53.41 | 53.41 | 53.41 |
| Inventories | 7.8 | -29.7 | 10.1 | 14.2 | .0 | .7 | .8 | .9 | 1.0 | 1.0 |
| Inventories, % | 268.57 | -12266.53 | 434.51 | 228.54 | 0 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 1.1 | 2.3 | .4 | .5 | .1 | .6 | .7 | .7 | .8 | .9 |
| Accounts Payable, % | 36.97 | 935.12 | 18.5 | 8.57 | 6.07 | 34.02 | 34.02 | 34.02 | 34.02 | 34.02 |
| Capital Expenditure | -18.7 | -14.7 | -8.9 | -10.8 | -11.0 | -1.8 | -2.0 | -2.2 | -2.4 | -2.6 |
| Capital Expenditure, % | -641.95 | -6066.53 | -380.13 | -175.02 | -647 | -100 | -100 | -100 | -100 | -100 |
| Tax Rate, % | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 |
| EBITAT | -123.8 | -142.1 | -120.3 | -122.8 | -163.3 | -1.7 | -1.8 | -2.0 | -2.1 | -2.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -175.2 | -111.5 | -132.7 | -130.3 | -154.9 | -1.8 | -1.9 | -2.1 | -2.2 | -2.5 |
| WACC, % | 22.87 | 22.41 | 22.43 | 22.47 | 24.26 | 22.89 | 22.89 | 22.89 | 22.89 | 22.89 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2 | |||||||||
| Terminal Value | -12 | |||||||||
| Present Terminal Value | -4 | |||||||||
| Enterprise Value | -10 | |||||||||
| Net Debt | -187 | |||||||||
| Equity Value | 177 | |||||||||
| Diluted Shares Outstanding, MM | 174 | |||||||||
| Equity Value Per Share | 1.02 |
What You Will Get
- Real AUTL Financial Data: Pre-filled with Autolus Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Autolus Therapeutics' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive AUTL Data: Pre-loaded with Autolus Therapeutics' historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, discount rates, tax implications, and capital investments.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Generate various forecasting scenarios to evaluate different valuation results.
- User-Friendly Interface: Intuitive, organized, and crafted for both professionals and newcomers.
How It Works
- Download the Template: Gain immediate access to the Excel-based AUTL DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically recalculates Autolus Therapeutics' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose This Calculator for Autolus Therapeutics (AUTL)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to Autolus’s valuation as you change the inputs.
- Preloaded Data: Comes equipped with Autolus's actual financial metrics for swift evaluations.
- Relied Upon by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use Autolus Therapeutics plc (AUTL)?
- Investors: Gain insights into innovative therapies and make informed investment choices.
- Healthcare Analysts: Utilize comprehensive data to evaluate the potential of cutting-edge treatments.
- Consultants: Tailor reports and presentations quickly using the latest research from Autolus Therapeutics.
- Biotech Enthusiasts: Expand your knowledge of advanced cell therapies and their market impact.
- Educators and Students: Leverage real-world case studies to enhance learning in biotechnology and pharmaceuticals.
What the Template Contains
- Historical Data: Includes Autolus Therapeutics plc’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Autolus Therapeutics plc’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Autolus Therapeutics plc’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.